

O0500 **Functional impairment of CMV-reactive cellular immunity during pregnancy**

Edith Reuschel², Sascha Barabas¹, Florian Zeman³, Hanna Bendfeldt¹, Anne Rascle^{*1},
Ludwig Deml¹, Birgit Seelbach-Göbel²

¹Lophius Biosciences GmbH, Regensburg, Germany, ²Klinik St. Hedwig, Obstetrics and Gynecology, Regensburg, , ³University of Regensburg, Center for Clinical Studies

Background: Cytomegalovirus (CMV) is the most common congenital viral infection in developed countries. Mother-to-child transmission can cause severe child disabilities, such as psychomotor retardation and hearing loss. Intact CMV-specific cell-mediated immunity prevents uncontrolled CMV replication in healthy individuals. This study aimed to determine whether CMV-specific cell-mediated immunity is impaired in pregnant women, thus potentially increasing the overall risk of active CMV replication and transmission.

Materials/methods: CMV-specific cell-mediated immunity in peripheral blood of 60 pregnant women was determined using T-Track[®] CMV, a novel immune-monitoring IFN- γ ELISpot assay quantifying CMV-reactive effector cells in response to T-activated[®] pp65 and IE-1 CMV proteins. T-Track[®] CMV results were analyzed in relation to CMV-IgG and CMV-IgM serostatus.

Results: CMV-specific cell-mediated immunity was detected in 65% of CMV-seropositive pregnant women. Interestingly, the overall number of CMV-reactive cells in pregnant women was significantly lower compared to that of a matched non-pregnant control group ($p < 0.001$). No significant difference in CMV-specific cell-mediated immunity was detected in the course of the three trimesters of pregnancy in CMV-IgG seropositive women. Remarkably, IE-1- and pp65-specific cellular immunity remained significantly lower postpartum (median days postnatal = 123) compared to the non-pregnant control group ($p < 0.001$ and 0.0032 for IE-1- and pp65-specific response, respectively).

Conclusions: Functional analysis of CMV-reactive immune cells using T-Track[®] CMV suggests a systemic down-regulation of CMV-specific cell-mediated immunity in pregnant women. Further studies are needed to investigate whether this may be indicative of a higher susceptibility to CMV reactivation or transmission to the fetus.